PT2769992T - Anticorpos humanos com elevada afinidade para o receptor de il-4 humana - Google Patents

Anticorpos humanos com elevada afinidade para o receptor de il-4 humana

Info

Publication number: PT2769992T
Authority: PT; Portugal
Prior art keywords: human; receptor; high affinity; antibodies; human antibodies
Prior art date: 2006-10-02

Application number

PT141620815T

Other languages

English (en)

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-02

Filing date

2007-10-02

Publication date

2021-03-11

2007-10-02 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2021-03-11 Publication of PT2769992T publication Critical patent/PT2769992T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Plant Pathology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Hematology (AREA)

PT141620815T 2006-10-02 2007-10-02 Anticorpos humanos com elevada afinidade para o receptor de il-4 humana PT2769992T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84869406P	2006-10-02	2006-10-02
US95773807P	2007-08-24	2007-08-24

Publications (1)

Publication Number	Publication Date
PT2769992T true PT2769992T (pt)	2021-03-11

Family

ID=39344836

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT141620815T PT2769992T (pt)	2006-10-02	2007-10-02	Anticorpos humanos com elevada afinidade para o receptor de il-4 humana
PT78671971T PT2069403E (pt)	2006-10-02	2007-10-02	Anticorpos humanos com elevada afinidade para o receptor de il-4 humana

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT78671971T PT2069403E (pt)	2006-10-02	2007-10-02	Anticorpos humanos com elevada afinidade para o receptor de il-4 humana

Country Status (35)

Country	Link
US (4)	US7605237B2 (pt)
EP (3)	EP2069403B1 (pt)
JP (1)	JP2010505418A (pt)
KR (1)	KR101474227B1 (pt)
CN (1)	CN101522716B (pt)
AU (1)	AU2007314522C9 (pt)
BR (1)	BRPI0719953B8 (pt)
CA (1)	CA2664343C (pt)
CO (1)	CO6160305A2 (pt)
CR (1)	CR10689A (pt)
CY (1)	CY1115551T1 (pt)
DK (2)	DK2769992T3 (pt)
DO (1)	DOP2009000058A (pt)
ES (2)	ES2466669T3 (pt)
HK (2)	HK1131790A1 (pt)
HR (2)	HRP20140512T1 (pt)
HU (1)	HUE054090T2 (pt)
IL (1)	IL197479A (pt)
LT (1)	LT2769992T (pt)
MA (1)	MA31138B1 (pt)
ME (1)	ME00616B (pt)
MX (1)	MX2009003393A (pt)
MY (1)	MY149079A (pt)
NI (1)	NI200900041A (pt)
NO (1)	NO347180B1 (pt)
NZ (1)	NZ576040A (pt)
PL (2)	PL2069403T3 (pt)
PT (2)	PT2769992T (pt)
RS (2)	RS53340B (pt)
RU (1)	RU2445318C2 (pt)
SI (2)	SI2069403T1 (pt)
TN (1)	TN2009000110A1 (pt)
UA (1)	UA98943C2 (pt)
WO (1)	WO2008054606A2 (pt)
ZA (1)	ZA200901617B (pt)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US20050144655A1 (en)	2000-10-31	2005-06-30	Economides Aris N.	Methods of modifying eukaryotic cells
ES2442615T5 (es)	2002-07-18	2023-03-16	Merus Nv	Producción recombinante de mezclas de anticuerpos
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
ES2408582T3 (es)	2003-05-30	2013-06-21	Merus B.V.	Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
KR101759457B1 (ko)	2007-12-21	2017-07-31	메디뮨 리미티드	인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
PT2147594E (pt)	2008-06-27	2014-02-17	Merus B V	Mamíferos não humanos que produzem anticorpos
US8871207B2 (en)	2008-07-25	2014-10-28	Humabs, LLC	Neutralizing anti-influenza A virus antibodies and uses thereof
US8685402B2 (en)	2008-07-25	2014-04-01	Institute For Research In Biomedicine	Neutralizing anti-influenza A virus antibodies and uses thereof
AU2014216019B2 (en) *	2008-10-29	2016-04-21	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
US9445581B2 (en)	2012-03-28	2016-09-20	Kymab Limited	Animal models and therapeutic molecules
EP4215043A1 (en)	2009-07-08	2023-07-26	Kymab Limited	Animal models and therapeutic molecules
US20130045492A1 (en)	2010-02-08	2013-02-21	Regeneron Pharmaceuticals, Inc.	Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en)	2010-02-08	2017-10-24	Regeneron Pharmaceuticals, Inc.	Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T5 (es)	2010-02-08	2021-02-22	Regeneron Pharma	Cadena ligera común de ratón
MX2012015298A (es)	2010-06-22	2013-05-01	Regeneron Pharma	Ratones con cadena ligera hibrida.
SG10201912639SA (en) *	2010-08-02	2020-02-27	Regeneron Pharma	Mice that make binding proteins comprising vl domains
MY158130A (en)	2010-10-06	2016-08-30	Regeneron Pharma	Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies
CN106432506A (zh)	2011-05-24	2017-02-22	泽恩格尼亚股份有限公司	多价和单价多特异性复合物及其用途
CN102830228B (zh) *	2011-06-15	2015-01-21	格诺思博生物科技(上海)有限公司	定量分析循环肿瘤细胞的试剂及试剂盒
JO3412B1 (ar) *	2011-06-17	2019-10-20	Regeneron Pharma	أجسام مضادة ل angptl3 واستخداماتها
KR102119840B1 (ko) *	2011-07-11	2020-06-09	아이크노스 사이언스 에스. 아.	Ox40에 결합하는 항체 및 이들의 용도
WO2013011347A1 (en)	2011-07-18	2013-01-24	Institute For Research In Biomedicine	Neutralizing anti-influenza a virus antibodies and uses thereof
LT3572517T (lt)	2011-08-05	2021-04-26	Regeneron Pharmaceuticals, Inc.	Humanizuotos universalios lengvosios grandinės pelės
MY170089A (en)	2011-09-16	2019-07-04	Regeneron Pharma	Methods for reducing lipoproten(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
DK3311661T3 (da)	2011-09-19	2022-07-11	Kymab Ltd	Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
EP2761008A1 (en)	2011-09-26	2014-08-06	Kymab Limited	Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
US9253965B2 (en)	2012-03-28	2016-02-09	Kymab Limited	Animal models and therapeutic molecules
CN104159444B (zh)	2011-12-20	2017-09-01	瑞泽恩制药公司	人源化的轻链小鼠
US20140013456A1 (en)	2012-03-16	2014-01-09	Regeneron Pharmaceuticals, Inc.	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
WO2013138681A1 (en)	2012-03-16	2013-09-19	Regeneron Pharmaceuticals, Inc.	Mice that produce antigen-binding proteins with ph-dependent binding characteristics
SI2825037T1 (sl)	2012-03-16	2019-08-30	Regeneron Pharmaceuticals, Inc.	Glodavci, ki izražajo PH občutljiva zaporedja imunoglobulina
US9334334B2 (en)	2012-03-16	2016-05-10	Regeneron Pharmaceuticals, Inc.	Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
GB2502127A (en)	2012-05-17	2013-11-20	Kymab Ltd	Multivalent antibodies and in vivo methods for their production
US10251377B2 (en)	2012-03-28	2019-04-09	Kymab Limited	Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
KR102545770B1 (ko)	2012-04-20	2023-06-21	메뤼스 엔.페.	Ig-유사 분자의 제조방법 및 제조수단
NZ744109A (en)	2012-08-21	2023-01-27	Regeneron Pharma	Methods for treating or preventing asthma by administering an il-4r antagonist
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
LT2840892T (lt) *	2013-02-20	2018-07-25	Regeneron Pharmaceuticals, Inc.	Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
ES2730011T3 (es) *	2013-02-20	2019-11-07	Innate Pharma	Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
US10150800B2 (en)	2013-03-15	2018-12-11	Zyngenia, Inc.	EGFR-binding modular recognition domains
US9788534B2 (en)	2013-03-18	2017-10-17	Kymab Limited	Animal models and therapeutic molecules
US9783618B2 (en)	2013-05-01	2017-10-10	Kymab Limited	Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en)	2013-05-02	2017-10-10	Kymab Limited	Antibodies, variable domains and chains tailored for human use
US11707056B2 (en)	2013-05-02	2023-07-25	Kymab Limited	Animals, repertoires and methods
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh)	2013-06-04	2020-07-01	美商再生元醫藥公司	藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RU2674680C2 (ru) *	2013-06-21	2018-12-12	Санофи Байотекнолоджи	Способы лечения полипоза носа путем введения антагониста il-4r
TWI682781B (zh)	2013-07-11	2020-01-21	美商再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
NL2013554B1 (en)	2013-10-01	2016-01-08	Kymab Ltd	Animal models and therapeutic molecules.
CN113667012B (zh)	2013-10-02	2024-07-12	免疫医疗有限责任公司	中和抗甲型流感抗体及其用途
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de)	2013-12-17	2015-10-20	Kymab Limited	Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP3145546B1 (en) *	2014-02-19	2020-12-09	Emergent BioSolutions Canada Inc.	Marburg monoclonal antibodies
IL315136A (en)	2014-02-21	2024-10-01	Sanofi Biotechnology	Methods for treating or preventing asthma by adding an IL-4R antagonist
CN106062000B (zh)	2014-02-28	2021-05-28	瑞泽恩制药公司	通过施用il-4r拮抗剂治疗皮肤感染的方法
RU2016141123A (ru)	2014-03-21	2018-04-23	Регенерон Фармасьютикалз, Инк.	Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
US10881085B2 (en)	2014-03-21	2021-01-05	Regeneron Pharmaceuticals, Inc.	Non-human animals that make single domain binding proteins
CN106573154B (zh)	2014-07-15	2021-06-15	免疫医疗有限责任公司	中和抗乙型流感抗体及其用途
WO2016023916A1 (en)	2014-08-12	2016-02-18	Kymab Limited	Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en)	2014-11-07	2016-05-12	Kymab Limited	Treatment of disease using ligand binding to targets of interest
US10066017B2 (en)	2014-11-14	2018-09-04	Sanofi Biotechnology	Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
KR20180010178A (ko)	2015-03-06	2018-01-30	소렌토 쎄라퓨틱스, 인코포레이티드	Jag1에 결합하는 항체 치료제
CN107438622A (zh)	2015-03-19	2017-12-05	瑞泽恩制药公司	选择结合抗原的轻链可变区的非人动物
AU2016242866B2 (en)	2015-03-30	2021-06-03	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to FC gamma receptors
ES2893148T3 (es) *	2015-04-02	2022-02-08	Intervet Int Bv	Anticuerpos contra el receptor alfa de la interleucina 4 canina
RS62446B1 (sr)	2015-06-01	2021-11-30	Medimmune Llc	Neutrališući vezujući molekuli protiv gripa i njihova primena
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
CN106939047B (zh) *	2016-01-04	2021-08-31	江苏怀瑜药业有限公司	一种pd-l1抗体及其制备方法
JP2019502715A (ja)	2016-01-13	2019-01-31	メディミューン，エルエルシー	Ａ型インフルエンザを治療する方法
MA44238A (fr)	2016-02-19	2018-12-26	Regeneron Pharma	Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
CN113372446A (zh) *	2016-06-08	2021-09-10	苏州康乃德生物医药有限公司	用于结合白细胞介素4受体的抗体
WO2018045130A1 (en)	2016-09-01	2018-03-08	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
CA3037499A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
WO2018075378A1 (en) *	2016-10-17	2018-04-26	Vanderbilt University	Human respiratory syncytial virus antibodies and methods of use therefor
TWI784988B (zh)	2016-12-01	2022-12-01	美商再生元醫藥公司	治療發炎症狀的方法
EP3554544A4 (en) *	2016-12-16	2020-07-29	Bluefin Biomedicine, Inc.	ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
WO2018190990A1 (en)	2017-04-13	2018-10-18	Regeneron Pharmaceuticals, Inc.	Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
CN107216388B (zh) *	2017-08-07	2020-05-05	广州泰诺迪生物科技有限公司	一种治疗丙型肝炎病毒药物的制备方法和用途
MA46269B1 (fr)	2017-08-18	2024-05-31	Regeneron Pharma	Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
US11034768B2 (en)	2017-10-30	2021-06-15	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an IL-4R antagonist
CN108373505B (zh)	2018-04-20	2019-08-20	北京智仁美博生物科技有限公司	抗il-4r抗体及其用途
EP3793597A1 (en)	2018-05-13	2021-03-24	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN110540590B (zh) *	2018-05-29	2023-08-18	康诺亚生物医药科技（成都）有限公司	一种自免疫抑制物的开发和应用
IL278267B1 (en) *	2018-07-16	2024-10-01	Regeneron Pharma	NON-HUMAN ANIMAL MODELS OF DITRA DISEASE AND USES THEREOF
CN112513090B (zh)	2018-08-24	2023-03-10	江苏恒瑞医药股份有限公司	结合人il-4r的抗体、其抗原结合片段及其医药用途
CN113166259A (zh) *	2018-11-09	2021-07-23	亚洲大学校产学协力团	对人IL-4受体α具有高亲和力的人抗体及其用途
CN111514292B (zh) *	2018-12-25	2023-06-20	江苏荃信生物医药股份有限公司	抗人白介素4受体α单克隆抗体的制药用途
MA55204A (fr)	2019-03-06	2022-01-12	Regeneron Pharma	Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
WO2020191346A1 (en)	2019-03-21	2020-09-24	Regeneron Pharmaceuticals, Inc.	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
US20220184127A1 (en) *	2019-04-08	2022-06-16	Phanes Therapeutics, Inc.	Humanized anti-dll3 chimeric antigen receptors and uses thereof
CN112010977B (zh) *	2019-05-29	2022-04-26	山东博安生物技术股份有限公司	抗白介素4受体(il-4r)的抗体及其应用
CN112279914A (zh) *	2019-07-25	2021-01-29	苏州丁孚靶点生物技术有限公司	Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
CN114173819A (zh)	2019-08-05	2022-03-11	瑞泽恩制药公司	通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
CN114173816A (zh)	2019-08-05	2022-03-11	瑞泽恩制药公司	通过施用il-4r拮抗剂治疗特应性皮炎的方法
AU2020399975A1 (en)	2019-12-09	2022-07-28	Sanofi Biotechnology	Methods for treating digitally-identified IL-4/IL-13 related disorders
EP3992974A1 (en)	2020-11-02	2022-05-04	Sanofi Biotechnology	Methods for treating digitally-identified il-4/il-13 related disorders
US20230075244A1 (en) *	2020-02-20	2023-03-09	The Feinstein Institutes For Medical Research	Agonist antibodies against endoglin and uses thereof
US20230088052A1 (en)	2020-02-21	2023-03-23	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmaceutical composition containing anti-il-4r antibody and use thereof
WO2021170020A1 (en) *	2020-02-27	2021-09-02	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Antibodies binding il4r and uses thereof
BR112022015363A2 (pt)	2020-03-27	2022-09-20	Regeneron Pharma	Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
JP2023521174A (ja) *	2020-04-10	2023-05-23	シアトルチルドレンズホスピタル（ディービーエイシアトルチルドレンズリサーチインスティテュート）	インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体
MX2022013034A (es)	2020-04-17	2022-11-09	Shanghaimabgeekbiotech Co Ltd	Anticuerpo anti-receptor a de interleucina-4 humana, metodo de preparacion y uso del mismo.
CN113549151A (zh) *	2020-04-24	2021-10-26	苏州康乃德生物医药有限公司	与人IL-4Rα中特定表位结合的抗体及其应用
KR20230015965A (ko)	2020-05-22	2023-01-31	리제너론 파아마슈티컬스, 인크.	Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
JP2023534024A (ja)	2020-07-17	2023-08-07	ジーアイイノベーション，インコーポレイテッド	Ｉｇｅｆｃ受容体アルファサブユニット細胞外ドメイン及び抗ｉｌ－４抗体を含む融合タンパク質並びにその融合タンパク質の使用
KR102697769B1 (ko)	2020-09-14	2024-08-23	아주대학교산학협력단	인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
WO2022076289A1 (en)	2020-10-05	2022-04-14	Sanofi Biotechnology	Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CA3202875A1 (en)	2020-12-22	2022-06-30	Huan Wang	Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
TW202241964A (zh) *	2021-01-08	2022-11-01	美商必治妥美雅史谷比公司	因子xia抑制劑之抗體及抗原結合肽及其用途
EP4274609A1 (en)	2021-01-08	2023-11-15	Regeneron Pharmaceuticals, Inc.	Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
CA3226781A1 (en)	2021-07-26	2023-02-02	Nikhil AMIN	Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TW202328183A (zh) *	2021-08-05	2023-07-16	美商美國禮來大藥廠	人類介白素-4受體α抗體
CA3227014A1 (en)	2021-08-23	2023-03-02	Ashish Bansal	Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2023069976A1 (en)	2021-10-20	2023-04-27	Sanofi Biotechnology	Methods for treating prurigo nodularis by administering an il-4r antagonist
IL313897A (en)	2021-12-30	2024-08-01	Regeneron Pharma	Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist
MX2024009080A (es)	2022-01-29	2024-07-30	Shanghai Shengdi Pharmaceutical Co Ltd	Conjugado farmacologico de glucocorticoide.
WO2023167855A1 (en)	2022-03-02	2023-09-07	Regeneron Pharmaceuticals, Inc.	Manufacturing process for high titer antibody
WO2023215750A2 (en)	2022-05-02	2023-11-09	Regeneron Pharmaceuticals, Inc.	Methods for reducing lipase activity
US20240024472A1 (en)	2022-05-02	2024-01-25	Regeneron Pharmaceuticals, Inc.	Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations
WO2024011251A1 (en)	2022-07-08	2024-01-11	Regeneron Pharmaceuticals, Inc.	Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
WO2024047021A1 (en)	2022-08-29	2024-03-07	Sanofi	Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
US20240141051A1 (en)	2022-11-01	2024-05-02	Regeneron Pharmaceuticals, Inc.	Methods for treating hand and foot dermatitis by administering an il-4r antagonist
WO2024112935A1 (en)	2022-11-23	2024-05-30	Regeneron Pharmaceuticals, Inc.	Methods for improving bone growth by administering an il-4r antagonist
US20240360232A1 (en)	2023-03-22	2024-10-31	Sanofi Biotechnology	Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
WO2024206341A1 (en)	2023-03-27	2024-10-03	Regeneron Pharmaceuticals, Inc.	Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7186A (en)		1850-03-19		fetchec
US809A (en)		1838-06-27		Improved mode of changing the poles of electro-magnets
GB8808015D0 (en)	1988-04-06	1988-05-05	Ritter M A	Chemical compounds
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
ES2301158T3 (es)	1992-07-24	2008-06-16	Amgen Fremont Inc.	Produccion de anticuerpos xenogenicos.
US5714146A (en)	1992-08-26	1998-02-03	Board Of Regents Of The University Of Washington	IL-4 bone therapy
EP0604693A1 (en) *	1992-12-29	1994-07-06	Schering-Plough	Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) *	1993-09-07	1995-07-06	Smithkline Beecham Corp	Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE16192152T1 (de) *	2000-05-26	2020-08-06	Immunex Corporation	Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
AR037456A1 (es) *	2001-11-30	2004-11-10	Biogen Inc	Anticuerpos contra proteinas quimiotacticas monocitarias
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
AU2004290017B2 (en) *	2003-11-07	2012-05-03	Immunex Corporation	Antibodies that bind interleukin-4 receptor
WO2005063817A2 (en) *	2003-12-22	2005-07-14	Amgen Inc.	Methods for identifying functional antibodies
AU2005219837A1 (en) *	2004-02-27	2005-09-15	Regeneron Pharmaceuticals, Inc.	IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) *	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) *	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
TW200902555A (en) *	2005-01-03	2009-01-16	Hoffmann La Roche	Antibodies against IL-13 receptor alpha 1 and uses thereof
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor

2007
- 2007-10-02 PT PT141620815T patent/PT2769992T/pt unknown
- 2007-10-02 DK DK14162081.5T patent/DK2769992T3/da active
- 2007-10-02 LT LTEP14162081.5T patent/LT2769992T/lt unknown
- 2007-10-02 MY MYPI20091180A patent/MY149079A/en unknown
- 2007-10-02 DK DK07867197.1T patent/DK2069403T3/da active
- 2007-10-02 KR KR1020097008844A patent/KR101474227B1/ko active IP Right Grant
- 2007-10-02 WO PCT/US2007/021210 patent/WO2008054606A2/en active Application Filing
- 2007-10-02 SI SI200731493T patent/SI2069403T1/sl unknown
- 2007-10-02 EP EP07867197.1A patent/EP2069403B1/en active Active
- 2007-10-02 PT PT78671971T patent/PT2069403E/pt unknown
- 2007-10-02 NZ NZ576040A patent/NZ576040A/en unknown
- 2007-10-02 UA UAA200904256A patent/UA98943C2/ru unknown
- 2007-10-02 RS RS20140308A patent/RS53340B/en unknown
- 2007-10-02 ES ES07867197.1T patent/ES2466669T3/es active Active
- 2007-10-02 CA CA2664343A patent/CA2664343C/en active Active
- 2007-10-02 AU AU2007314522A patent/AU2007314522C9/en active Active
- 2007-10-02 RU RU2009116608/10A patent/RU2445318C2/ru active
- 2007-10-02 MX MX2009003393A patent/MX2009003393A/es active IP Right Grant
- 2007-10-02 HU HUE14162081A patent/HUE054090T2/hu unknown
- 2007-10-02 RS RS20210392A patent/RS61650B1/sr unknown
- 2007-10-02 ME MEP-2009-111A patent/ME00616B/me unknown
- 2007-10-02 PL PL07867197T patent/PL2069403T3/pl unknown
- 2007-10-02 US US11/906,517 patent/US7605237B2/en active Active
- 2007-10-02 JP JP2009531433A patent/JP2010505418A/ja active Pending
- 2007-10-02 NO NO20091758A patent/NO347180B1/no unknown
- 2007-10-02 BR BRPI0719953A patent/BRPI0719953B8/pt active IP Right Grant
- 2007-10-02 PL PL14162081T patent/PL2769992T3/pl unknown
- 2007-10-02 EP EP20207210.4A patent/EP3845563A3/en active Pending
- 2007-10-02 ES ES14162081T patent/ES2859825T3/es active Active
- 2007-10-02 SI SI200732172T patent/SI2769992T1/sl unknown
- 2007-10-02 EP EP14162081.5A patent/EP2769992B1/en active Active
- 2007-10-02 CN CN200780036872.1A patent/CN101522716B/zh active Active
2009
- 2009-03-06 ZA ZA2009/01617A patent/ZA200901617B/en unknown
- 2009-03-08 IL IL197479A patent/IL197479A/en active IP Right Grant
- 2009-03-24 CR CR10689A patent/CR10689A/es unknown
- 2009-03-30 NI NI200900041A patent/NI200900041A/es unknown
- 2009-03-31 TN TN2009000110A patent/TN2009000110A1/fr unknown
- 2009-04-01 DO DO2009000058A patent/DOP2009000058A/es unknown
- 2009-04-30 MA MA31835A patent/MA31138B1/fr unknown
- 2009-04-30 CO CO09044043A patent/CO6160305A2/es unknown
- 2009-09-04 US US12/554,029 patent/US7794717B2/en active Active
- 2009-10-21 HK HK09109758.4A patent/HK1131790A1/xx unknown
2010
- 2010-06-23 US US12/821,499 patent/US8092802B2/en active Active
2011
- 2011-12-02 US US13/309,594 patent/US8338135B2/en active Active
2014
- 2014-06-03 HR HRP20140512TT patent/HRP20140512T1/hr unknown
- 2014-08-07 CY CY20141100620T patent/CY1115551T1/el unknown
2015
- 2015-02-04 HK HK15101192.7A patent/HK1200846A1/xx unknown
2021
- 2021-03-10 HR HRP20210408TT patent/HRP20210408T1/hr unknown

Also Published As

Publication number	Publication date
EP2769992B1 (en)	2020-12-30
LT2769992T (lt)	2021-04-12
MEP11109A (en)	2011-12-20
HK1200846A1 (en)	2015-08-14
US7794717B2 (en)	2010-09-14
DOP2009000058A (es)	2009-04-30
PT2069403E (pt)	2014-07-18
CA2664343C (en)	2016-04-26
RS61650B1 (sr)	2021-04-29
KR101474227B1 (ko)	2014-12-18
WO2008054606A2 (en)	2008-05-08
CR10689A (es)	2009-06-24
SI2769992T1 (sl)	2021-04-30
MY149079A (en)	2013-07-15
BRPI0719953B1 (pt)	2019-04-24
IL197479A (en)	2014-03-31
EP2769992A3 (en)	2015-01-21
NO20091758L (no)	2009-05-04
PL2069403T3 (pl)	2015-08-31
UA98943C2 (ru)	2012-07-10
JP2010505418A (ja)	2010-02-25
SI2069403T1 (sl)	2014-09-30
US20080160035A1 (en)	2008-07-03
CN101522716A (zh)	2009-09-02
EP2069403B1 (en)	2014-05-07
EP2769992A2 (en)	2014-08-27
AU2007314522C1 (en)	2013-06-27
AU2007314522A8 (en)	2013-04-11
RU2445318C2 (ru)	2012-03-20
WO2008054606A3 (en)	2009-02-05
CA2664343A1 (en)	2008-05-08
IL197479A0 (en)	2011-08-01
US8338135B2 (en)	2012-12-25
EP3845563A2 (en)	2021-07-07
AU2007314522C9 (en)	2013-08-01
AU2007314522A2 (en)	2009-07-02
NI200900041A (es)	2011-10-17
ZA200901617B (en)	2009-12-30
HRP20140512T1 (hr)	2014-07-04
HRP20210408T1 (hr)	2021-04-30
US20100021476A1 (en)	2010-01-28
US8092802B2 (en)	2012-01-10
TN2009000110A1 (en)	2010-08-19
RS53340B (en)	2014-10-31
CO6160305A2 (es)	2010-05-20
RU2009116608A (ru)	2010-11-10
US20120135010A1 (en)	2012-05-31
EP2069403A2 (en)	2009-06-17
ES2859825T3 (es)	2021-10-04
AU2007314522B8 (en)	2013-04-11
AU2007314522B2 (en)	2013-02-21
DK2769992T3 (da)	2021-03-22
MX2009003393A (es)	2009-05-11
DK2069403T3 (da)	2014-07-28
HUE054090T2 (hu)	2021-08-30
AU2007314522A1 (en)	2008-05-08
CY1115551T1 (el)	2017-01-04
KR20090088865A (ko)	2009-08-20
US20100291107A1 (en)	2010-11-18
NZ576040A (en)	2011-06-30
US7605237B2 (en)	2009-10-20
NO347180B1 (no)	2023-06-19
PL2769992T3 (pl)	2021-08-02
BRPI0719953B8 (pt)	2021-05-25
ME00616B (me)	2011-12-20
MA31138B1 (fr)	2010-02-01
HK1131790A1 (en)	2010-02-05
EP3845563A3 (en)	2021-11-24
BRPI0719953A2 (pt)	2014-04-29
ES2466669T3 (es)	2014-06-10
CN101522716B (zh)	2013-03-20

Publication	Publication Date	Title
HK1200846A1 (en)	2015-08-14	High affinity human antibodies to human il-4 receptor il-4
HRP20130467T1 (en)	2013-06-30	High affinity human antibodies to human il-4 receptor
HUS1700029I1 (hu)	2017-07-28	Nagy affinitású PCSK9 elleni humán testek
EP2220247A4 (en)	2011-10-26	ANTIBODIES DIRECTED AGAINST LRP6
IL197937A0 (en)	2011-08-01	Antibodies to lymphotoxin-alpha
ZA200902346B (en)	2010-07-28	Antibodies to lymphotoxin-alpha
ZA200809771B (en)	2009-11-25	High affinity antibodies to human IL-6 receptor